Multicenter phase 2 study of combined gemcitabine and epirubicin as second-line treatment for patients with advanced ovarian cancer

International Journal of Gynecological Cancer

Volumn 20, Issue 6, 2010, Pages 953-957

  Murgia, Viviana ^a   Sorio, Roberto ^b   Griso, Claudia ^c   Caffo, Orazio ^a   Arcuri, Carmela ^a   Ferro, Antonella ^a   Caldara, Alessia ^a   Scalone, Simona ^b   Arisi, Emilio ^a   Galligioni, Enzo ^a  

^a SANTA CHIARA HOSPITAL   (Italy)

^b Oncology Centre of Aviano   (Italy)

^c Department of Medical Oncology   (Italy)

Author keywords

Epirubicin; Gemcitabine; Ovarian cancer

Indexed keywords

DEXAMETHASONE; EPIRUBICIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RELAPSE; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDOMETRIOID CARCINOMA; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; INFORMED CONSENT; LEUKOPENIA; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; OVARY ADENOCARCINOMA; OVARY CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; CANCER STAGING; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; ITALY; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORTALITY; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PATHOLOGY; REMISSION; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; ITALY; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; REMISSION INDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 77956830441     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181e4a6c1     Document Type: Article

References (20)

1. Harries M, Gore M. Part II: chemotherapy for epithelial ovarian cancer - treatment of recurrent disease. Lancet Oncol. 2002;3:537-545. (Pubitemid 34993641)
2. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21:3194-3200.
3. Markman M, Webster K, Zanotti K, et al. Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer. Gynecol Oncol. 2003;90:593-596.
4. Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001;19:3312-3322.
5. Hansen SW, Tuxen MK, Sessa C. Gemcitabine in the treatment of ovarian cancer. Ann Oncol. 1999;10:51-53.
6. Pelaez I, Lacave AJ, Palacio I, et al. Phase II trial of epirubicin at standard dose in relapsed ovarian cancer. Eur J Cancer. 1996;32A:899-900.
7. Zoli W, Ricotti L, Barzanti F, et al. Schedule-dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines. Int J Cancer. 1999;80: 413-416.
8. Pignata S, Varriale E, Casella G, et al. A phase I study of gemcitabine and epirubicin for the treatment of platinum-resistant or refractory advanced ovarian cancer. Ann Oncol. 2000;11:613-616.
9. Rustin GJ, Nelstrop AE, McClean P, et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol. 1996;14:1545-1551.
10. Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003;361:2099-2106.
11. Cantu MG, Buda A, Parma G, et al. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol. 2002;20:1232-1237.
12. Pignata S, Ferrandina G, Scarfone G, et al. Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer. Results from the SOCRATES Retrospective Study. Oncology. 2006;71:320-326.
13. Uziely B, Jeffers S, Isacson R, et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol. 1995;13: 1777-1785.
14. Vermorken JB, Kobierska A, Chevallier B, et al. A phase II study of high-dose epirubicin in ovarian cancer patients previously treated with cisplatin. EORTC Gynecological Cancer Cooperative Group. Ann Oncol. 2000;11:1035-1040.
15. Friedlander M, Millward MJ, Bell D, et al. A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann Oncol. 1998;9:1343-1345.
16. Ferrandina G, Ludovisi M, Lorusso D, et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol. 2008;26:890-896.
17. Mutch DG, Orlando M, Goss T, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2007;25:2811-2818.
18. Ferrandina G, Paris I, Ludovisi M, et al. Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survival. Gynecol Oncol. 2005;98:267-273.
19. Thigpen T. The role of gemcitabine-based doublets in the management of ovarian carcinoma. Semin Oncol. 2002;29: 11-16.
20. Markman M. Second-line treatment of ovarian cancer with single-agent gemcitabine. Semin Oncol. 2002;29:9-10. (Pubitemid 34163836)